'Pivotal' Time for DLBCL Treatment Options

The Food and Drug Administration, in a flurry of activity, approved three new medications across a three-month period earlier this year.

Related Keywords

Mike Peters ,Manali Kamdar ,Leukemia Lymphoma Society ,Drug Administration ,University Of Colorado Anschutz Medical Campus ,Colorado Anschutz Medical Campus ,Lymphoma Society ,Lymphoma ,Diffuse Largeb Cell Lymphoma ,Non Hodgkin Lymphoma ,